

Index

a

- 4-AA 189–190
- α -acetamido benzocyclic ketones 159
- (*Z*)- α -acetamidocinnamic acid methyl ester (MAC) 319
- acetophenone reduction 222, 291
- applications 232–235
- aqueous conditions 231–232
- formic acid 228–231
- hydrogenation with hydrogen gas 232
- racemic catalysts 232
- acetylenic α -methylated β -hydroxy Weinreb amide 159
- acetylenic ketones reduction 73, 152, 235
- activated ketones 308, 309, 313, 314
- α -*N*-acylamino- β -keto esters 244, 245
- 2-acylamino-3-oxobutyrates 129
- aliphatic aldehydes 351
- aliphatic β -dehydroamido acid esters 37
- aliphatic ketones 62, 131, 350, 358, 359
- aliphatic β -substituted substrates 165
- Aliskiren 205–207
- alkenyl alkyl ketones 66–71
- alkenyl aryl ketones 67, 69
- 1,3-alkoxy/aryloxy propanones 239
- α -alkoxy β -ketoesters 153
- δ γ -alkoxy- β -hydroxy- α -alkyl-substituted Weinreb amides 158
- α -alkoxy-substituted β -ketoesters 153
- α -substituted ketones 130
- α -substituted β -keto esters
- α -amino β -keto esters 144–151
- α -substituted β -keto esters 151–156
- alkyl aryl *N*-phenyl imines 282
- N*-alkyl imines 355, 356
- tert*-alkyl ketones 61, 62, 83
- alkyl methyl ketones 57–59
- alkynyl alkyl ketones 71–73
- alkynyl ketones 71–74, 83
- anti* α -amino- β -hydroxyesters 145
- amides 33, 36, 147, 239, 244, 245
- amines 45, 57, 116, 212, 228, 244, 257, 262, 281, 288–290, 294, 295, 297, 300, 301, 345, 347, 348, 350–356, 358, 366, 367
- trans*- β -amido alcohols 160
- 3-amido-2-arylpiperidinium hydrochlorides 264
- α -amino acid hydrochlorides 347
- β -amino alcohols 76, 107, 196, 239
- α -amino aliphatic ketones 131
- (*R*)-3-amino-1-butanol 181–182
- 2-aminochalcones 331
- cis*- α -aminocycloalkanols 135
- cis*-amino cycloalkanols 243
- cis*-1-amino-2-indanol 188
- α -amino- β -keto ester hydrochlorides 145–147, 149, 150
- α -aminoketones 73–77, 241, 243
- β -aminonitroolefins 347
- 2-aminophenol 358
- 8-aminoquinolines 367
- α -amino β -unfunctionalized alcohols 134
- α -amino β -unfunctionalized *N,N*-disubstituted ketones 134
- anomalous dispersion method 2
- anti*- β -amino α -hydroxyesters 165
- antidepressant reboxetine 158
- Apremilast 184

- aprepitant 187, 189
 aromatic α -aminoketone hydrochlorides 131
 aromatic ketones 57, 60, 66, 68, 95–100, 130, 144, 232, 353
 aromatic/trichloromethyl ketones 239
 2-aryl-1-tetralones 141, 142
 artificial IRED (ATHase) 295
 artificial metalloenzymes 295–297
 β -aryl β -acetylamino acrylonitriles 26, 27
 aryl α -alkoxy β -ketoesters 153
 3-aryl benzoxazine derivatives 330
 α -aryl enacetamides 28
 α -aryl- γ -keto malononitriles 167
syn aryl β -hydroxy α -dibenzylamino esters 151
 aryl β -keto α -amino esters 148
 β -aryl α -keto esters 163
 aryl heterocycloalkyl ketones 132
 2-aryl indoline 359
 aryl ketones 88–90, 92, 94, 95, 97, 98, 100–121, 141, 154, 248, 274
 aryl methyl *N*-arylimines 282
 β -aryloxy alcohols 132
 2-arylquinolines 259, 369
 2-aryl substituted enamides 329
 asymmetric additions to ketenes 7
 Asymmetric Counteranion Directed Catalysis (ACDC) 343
 asymmetric Diels–Alder reactions 6
 asymmetric DKR-hydrogenation 157
 asymmetric hydrogenation
 alkenyl aryl ketones 69
 alkyl ketones 57–65
 alkyl methyl ketones 58, 59
 alkynyl ketones 71–74
 allylic alcohol reactant 10
 α -aminoketones 73
 benzylideneacetone 67
 N-Boc-imidazoles 271
 chiral arene–ruthenium-diamine complexes 95–96
 chiral bidentate P,N ligands 37
 chiral iridium catalysts 98
 chiral osmium and iron catalysts 101
 chiral phosphine-phosphoramidite and phosphine-phosphite ligands 31
 chiral ruthenium catalysts 90
 chiral ruthenium-diphosphine/diamine catalysts phosphine ligands 91–95
 copper catalyst 102
 dialkyl ketones 65
 diastereoselectivity 9–10
 of enamide 177
 ethyl 2-phenylcinnamate 8
 first row transition metal catalysts 48
 O- and *S*-heteroarenes 273
 α -hydroxyketones 77, 79, 80
 2-hydroxypyrimidines 272
 imine–amine hydrogenation 9
 indoles and pyrroles 265
 iridium catalysts 36
 isoquinolines 262
 ketone 185
 monodentate phosphorus ligands 33
 multi *N*-heterocycles 268
 α -oxophosphonates 80
 with palladium catalysts 46
 phenanthridines 273
 prolyl-dehydrophenylalanines 9
 pyrazol-5-ols 272
 of pyridines and pyrazines 263
 pyrimidines 271
 quinazolinium salts 273
 quinolines 257
 quinoxalines 260
 3-quinuclidinone 77
 rhodium catalysts 34
 β -aryl β -acetylamino acrylonitriles 27
 chiral bisphosphine ligands 25–27
 chiral ferrocenyl bisphosphine ligands 27–31
 ruthenium catalysts 43
 self-assembled diphosphine ligands 33
 single-handed α -quartz powder 8
 tert-alkyl ketones 62
 and transfer hydrogenation 25
 α , β -unsaturated ketones
 alkenyl alkyl ketones 66–71
 alkynyl alkyl ketones 71–73
 asymmetric ketone reductions 7, 221

- asymmetric reductions 9, 55,
 226–248
 asymmetric rhodium hydrogenation
 first Rh-catalyzed asymmetric
 hydrogenations 12
 neomenthyl-diphenyl phosphine 13
 phosphorus chirality 12
 practical catalytic asymmetric
 hydrogenation 14
 rhodium–phosphine hydrogenation
 catalysts 11
 asymmetric synthesis
 asymmetric additions to ketenes 7
 asymmetric Diels–Alder reactions 6
 asymmetric induction 4
 asymmetric ketone reductions 7
 catalytic asymmetric aldol
 condensations 8
 chiral chromatography and NMR
 techniques 5
 Cram’s original model 5
 decarboxylation of methylethylmalonic
 acid 4
 hydroboration of alkenes 6
 asymmetric transfer hydrogenation (ATH)
 34–36, 42–45, 62, 65, 71, 74, 76, 81,
 82, 87, 88, 95, 103–121, 129, 142,
 152, 153, 159, 190, 211, 221–248,
 256, 261, 288–293, 315, 316, 326,
 327, 330, 339–369
 atorvastatin calcium salt 197–198
 Augustine-method 316–321, 325
 azaindolines 268
- b**
- Baiker’s experimental setup 310
 BASF’s citral-based menthol synthesis
 202
 Benzofurans 138, 274, 275
 benzophenone ketones reduction
 235–237
 benzothiazines 298, 351
 benzothiazolines 357–359
 benzothiophenes 274, 275
 benzoxazines 299, 330, 351, 357, 369
 benzoxazinones 351
 α -(*N*-benzoyl-*N*-methylamino)
 propiophenone 131, 132
 2-benzoylmorpholin-3-ones 158
- N*-benzyl 5-acetyluracil 159
 benzyl amine 353
 benzylammonium trifluoroacetate 345
 benzylideneacetone 66, 67, 71
 2-benzylidenemalononitrile 363, 364
N-benzyl-pyridium bromides 263
 β -amino acids 182
 β -hydroxyester derivatives 154, 197
anti β -amido α -hydroxy esters 165
 β -dehydroamido acid esters 37, 42
 bidentate oxazoline-aminophosphine 39
 (*S*)-Binapine ligand 48
 Binol-based Brønsted-acid 331
 biocatalytic imine reduction
 artificial metalloenzymes 295–297
 imine reductases (IREDs) 297–301
 Biot’s Law 2
 biphosphine–thiourea ligand 288
 Boc-amino amide ligand 115
 α -branched aromatic ketones 130
 α -bromoindenones 162
 Brønsted acids 102, 264, 272, 345, 349,
 361
 bronchodilator drug 233
 1,2-bis(*tert*-butylmethylphosphino)
 benzene ligand 26
 γ -butyrolactones 163
- C**
- C₃*-TunePhos 66, 187
 C=C bond reductions
 β -aminonitroalkanes 347
 1,1-diarylethanes 347
 ACDC strategy 344
 Brønsted acid catalysis 345
 citral 344
 enal 342, 345
 iminium ion-phosphate pair 345
 MacMillan-type imidazolidinone 341
 β -nitroesters 346
 nitroolefins 346
 resin-supported peptide 345
 α,β -unsaturated aldehydes 341, 342,
 344
 α,β -unsaturated ketones 345
 C=N bond reductions
 ACE inhibitor 352
 aliphatic aldehydes 351
 aliphatic ketones 359

- C=N bond reductions (*contd.*)
- N*-alkyl imines 356
 - alkyl-substituted substrates 351
 - α -amino acid hydrochlorides 347
 - 2-aminophenol 358
 - aromatic ketones 353
 - 2-aryl indoline 359
 - α -branched ketones 352
 - 3-hydroxyisoindolinones 353
 - benzodiazepinones and 3H-indoles 351
 - benzothiazolines 357–359
 - benzylamine 352
 - chiral phosphoric acid (CPA) 348
 - dihydrobenzodiazepines 360
 - dihydrophenanthridine (DHPD) 353
 - Hantzsch ester 348, 350
 - 3H-indolines 354
 - imines 349, 352, 358
 - 2-naphthalenecarbaldehyde 358
 - N*-H imines 357
 - racemic α -branched ketones 351
 - self-redox reaction 357
 - 2-substituted and 2,3-disubstituted indolines 354
 - 3-substituted isoindolinones 353
 - tetrahydroquinolines 354
 - carbapenem antibiotics 189–190
 - carbonic anhydrase inhibitor 186
 - cascade reaction
 - azadecalines 362
 - aza-Friedel–Crafts reaction 363
 - 2-benzylidenemalononitrile 363
 - Brønsted acid catalysis 361
 - chlorination and fluorination 361
 - defined 359
 - 2,3-disubstituted indoles 364
 - imidazolidinone organocatalyst 360
 - reduction–Michael cyclization 360
 - tetrahydropyridines 362
 - α,β -unsaturated ketones 362
 - catalytic asymmetric aldol condensations 8
 - catalytic hydrogenation 8
 - α -CF₃-substituted 1,3-diols 142
 - chemzyme reactor 328
 - β -chiral acid esters 332
 - chiral 1,2-amino alcohols 196
 - chiral alcohols 120
 - chiral amines 345
 - chiral β -aryloxy alcohols 168
 - chiral bisphosphine ligands 25
 - chiral diaminodiphosphine ligand 120
 - chiral diazepane 211
 - chiral ferrocenyl bisphosphine ligands 27
 - chiral β -hydroxy α -amino phosphonates 160
 - chiral imidazolidinium salt 345
 - chiral iridium catalysts 98, 116
 - diamine and related ligands 113
 - multidentate aminophosphine ligands 117
 - chiral iron complex 118
 - chiral manganese catalyst 119
 - chiral metal catalysts 102
 - chiral osmium catalyst 100
 - chiral osmium complex 119
 - chiral rhodium catalysts 116
 - diamine and related ligands 113–116
 - multidentate aminophosphine ligands 117
 - chiral ruthenium catalysts
 - bidentate ligands 107–111
 - chiral arene ruthenium–*N*-sulfonylated 1,2-diamine complexes 104–107
 - chiral arene–ruthenium–diamine complexes 95–96
 - chiral ruthenium–diphosphine/diamine catalysts 90–95
 - chiral ruthenium–phosphine–oxazoline catalysts 96–97
 - tetradentate ligands 98
 - tridentate pincer ligands 97–98
 - tridentate and tetradentate ligands 111
 - chiral ruthenium–phosphine–oxazoline catalysts 96
 - chirally modified metal surfaces
 - alkaloids 308
 - Baiker's experimental setup 310
 - chiral modifier and trifluoroacetic acid (TFA) 310
 - enantioselective flow hydrogenation 309
 - ethyl benzoylformate (EBF) 311
 - ethyl 2-nitro-3-methylphenylpyruvate 314

- ethyl-2-oxo-4-phenylbutyrate 312
 α -ketoesters 309
 ligand acceleration (LA) effect 311
 Orito reaction 313
 1-phenyl-1,2-propanedione 311
 Pt/alumina surfaces 310
anti-chlorohydrins 165
 β -chloro- α -ketoesters 165
 cholesteryl transfer protein (CETP)
 inhibitors 94
 chronic obstructive pulmonary disease
 (COPD) 233
 (*R*)-clorprenaline 196
 continuous-flow system 307–310, 313,
 321–324
 continuous microreactor system 313
 crizotinib 94, 192–194
 3C-tethered catalyst 232–235, 237, 246
 cyclic enamides 33, 39, 40
trans-cycloalkyl amines 137
 β -cyclodextrin 64, 65
 cyclohexanols 156
 cyclohexanones 135, 339
 1-cyclohexenyl methyl ketone 71
 1,3-cyclopentadione 240
 cyclopentanols 140, 156
- d**
- daldinin A 138
 dearomatization 363–369
 α,β -dehydro- α -acetamido 159
 α -dehydroamido acid esters 37, 175
 α -dehydroamino acid methyl esters
 329
 dehydroxylated silica 323
 density functional theory (DFT) 100,
 259, 345
 1,3-dialkoxy propanones 240
 α -*N,N*-dialkylamino aliphatic ketones
 131
 dialkyl ketones 58, 62, 65, 237
 1,1-diarylethanes 347
minor diastereomer 221
 1,4-diazabicyclo[2.2.2]octane (DABCO)
 188
 dibenzylammonium trifluoroacetate 341
 dibutyl itaconate (DBI) 321, 322
 (*S*)-1-(2,6-dichloro-3-fluoro-phenyl)
 ethanol 193
- cis*-2,3-dihydrobenzofuran-3-ol derivatives
 139
rac-2,3-dihydrobenzofuran α -substituted
 ketones 138, 139
 (*R*)-dihydrodaidzein 138
 dihydronaphthalene 339
 dihydrophenanthridine (DHPD) 260,
 273, 353
 3,4-dihydro-2H-pyran-carbonitriles 167,
 168
 1,4-dihydropyridine 340
 1,2-dihydroquinoline 359, 366
 3,4-dihydroquinoline 259
 α,δ -diketo esters 164
 1,2-diketones 167, 359
 3,5-dimethoxy substituents 231
 3,5-dimethyl 231
 2-dimethylamino-1-phenylethyl amine
 (DMAPEN) 94
N,N-dimethylanilinium bromide 265
 dimethyl 1,4-dihydroterephthalate
 339
 dimethyl itaconate (DMIT) 33, 317, 319,
 323
 2,2-dimethyl-6-(2-oxoalkyl/oxoaryl)-1,3-
 dioxin-4-ones 237
 3,5-dimethylphenyl groups 92, 119
N-(diphenylphosphinyl) ketimines 293
 3,5-diphenyl substrate 247
 dimethyl terephthalate 339
 (*S*)-2,6-dimethyltyrosine motifs 182,
 183
syn-1,2-diol derivatives 153
N-(diphenylphosphinyl)imines 287
 diphosphine ligand 25, 27, 33, 43, 46, 66,
 90–92, 100, 102, 104, 109, 110, 112,
 117, 119, 129, 208, 257, 258, 263,
 282, 286, 288
N,N-disubstituted *cis*- α -
 aminocycloalkanols 135
 3,5-disubstituted *N*-benzyl pyrazinium
 salts 265
 α,α' -disubstituted cyclic ketones 142
 α,β -disubstituted cyclic ketones 143
 β,β -disubstituted enone 69
 2,3-disubstituted 1-indanones 144, 243,
 244
 3,4-disubstituted isoquinolines 263
 β,β -disubstituted nitroolefins 346

2,3-disubstituted quinoxalines 260, 261
 DKR hydrogenation reaction conditions 145
 Dolutegravir 181
 L-DOPA 14, 15, 25, 175, 177, 212
 Dorzolamide 186–187
 duloxetine 185–186
 dynamic kinetic resolution (DKR) 129, 350
 cis-amino cycloalkanols 243
 2,3-disubstituted 1-indanones 243, 244
 dibenzylamino β -ketoesters 246
 fluorinated substrates 245
 cis- β -heteroaryl amino cycloalkanols 244
 β -Keto esters and amides 244
 metabotropic glutamate receptor 5 (mGluR5) 243
 β -substituted chromanones 246
 2-substituted cyclic ketone 242
 3C tethered catalyst 246
 unprotected α -amino ketones 245

e
 enals 341, 345
 enamide, asymmetric hydrogenation of
 (*R*)-3-amino-1-butanol 181–182
 Apremilast 184
 (*S*)-2,6-dimethyltyrosine 182–184
 L-DOPA 177
 ramipril 178–179
 sitagliptin 179–181
 β -enamine amides 45, 179
 enamines 38, 42, 184, 393
 enantioselective reduction 63, 130, 221, 248, 261, 341–345, 359
 enol esters 28, 33
ent-trans- β -amido alcohols 160
 eslicarbazepine 234
 eslicarbazepine acetate 234
 ethyl benzoylformate (EBF) 311
 ethyl β -methyl cinnamates 39
 (*S*)-ethyl 4-chloro-3-hydroxybutanoate 197, 198
 ethyl 2-nitro-3-methylphenylpyruvate 314
 Ezetimibe 199–201, 233

f

 favored transition state model 67
 Felkin–Anh type transition state 130
 ferrocenyl bisphosphine ligands 27–31
 ferrocenyl ketones 240
 fixed-bed continuous-flow reactor 314
 fixed-bed plug flow reactor 312, 313
 flow process 245, 311, 314, 320, 321, 324, 333
 fluorinated substrates 245
 β -fluoro- α -ketoesters 165
 (*S*)-5-fluoropyrimidin-2-yl-ethanamine 320, 324
 Flurbiprofen 204–205
 3-formylchromone derivatives 141
 fosaprepitant 187
 Friedel–Crafts reaction 267, 363, 368
 frustrated lewis pair (FLP) 255, 259, 294
 functionalized aldehydes 355
 furans 273–275, 365
 furbiprofen 204

g

(–)-galanthamine 136
 gas-chromatograph (GC) 320
 glucagon receptor antagonist 133
 glycolic acid scaffolds 164
 gymnangiamide 146

h

Hantzsch diethyl ester 345
 Hantzsch dihydropyridine 330, 331, 349
 Hantzsch esters 340, 341, 343, 345–347, 354, 356, 358, 368
 heteroaromatics 78, 97, 150, 165, 166, 231, 235, 255–303, 368
cis- β -heteroaryl amino cycloalkanols 137, 139, 140, 243, 244
 heteropolyacid (HPA) 316
 hexafluoroisopropanol (HFIP) 267
cis-hexahydroterephthalate 339
 3H indolines 354
 homogeneous asymmetric hydrogenation
 chemzyme reactor 327–328
 micromesh continuous reactor 326
 microreactors 328
 modified borohydride 326
 polysiloxane moiety 327
 tetralone 328

- transition metal contaminant, removal
 of 326
 tube-in-tube reactor 326
 Homo-Roche ester derivatives 42
 hydrazones 287
 hydrobenzoin 167
 hydroboration of alkenes 6
 hydrogenated dihydrophenanthridine
 260
 hydrogenation reaction 8, 10, 27, 99,
 129, 133, 135, 145, 307–309, 316,
 333, 339–369
 hydrogen donors 43, 45, 47, 48, 87, 103,
 104, 106, 107, 339
 2-hydroxy acetophenones 231
anti β -hydroxy- α -amino acids 148
 3-(2-hydroxy-2-arylethyl)isobenzoburan-
 1(3H)ones 166
 4-hydroxy-benzo- δ -and 3-(α -hydroxy-
 arylmethyl)-benzo- γ -sultams 248
 β -hydroxy α -amino phosphonates 160,
 161
 β' -hydroxy- β -amino acids 155
 β -hydroxy- γ -lactams 157, 158
 4-hydroxybutanal 228
 α -hydroxy esters 239
 3-hydroxyisoindolinones 353
 α -hydroxyketones 77–80
 β -hydroxy lactams 157
cis-3-(hydroxymethyl)-chroman-4-ols
 141
 (hydroxyphenylmethyl)morpholin-3-one
 derivatives 158
 4-hydroxyproline 16
 β -hydroxy sulfonamides 162
 β -hydroxy sulfones 161–163
- i**
- Ibuprofen 204–205
 imidazo[1,2-*a*]pyridines 268
 imine 209, 281–301, 349, 358
 reduction 247, 358
 immobilized systems
 Augustine-method 316–321
 covalently anchored ligands 315–316
 ionic liquid phases, transition metal
 catalysts 321–325
 impressive turnover number (TON) 282
 indoles 265–267
- indolines 265, 267, 298, 354
 interleukin-2 inducible T-cell kinase
 (ITK) 235
 iridium 286, 292
 catalysts
 (P,N) ligands 282–286
 (P,P) ligands 281–282
 P-monodentate ligands 286–287
 iridium-catalyzed asymmetric
 hydrogenation
 chiral bidentate ferrocenyl ligands
 36–37
 iron catalysts 101, 117–119, 293
 isomers 146
 isoquinolines 262
- j**
- JAK-2 kinase inhibitor 320
- k**
- β -keto amide 242
 β -keto- α -amino acid esters 145
 β -keto- γ -lactams 157
 β -ketoester 244, 340
 β -keto ester precursor 241
 ketones 353
 asymmetric hydrogenation of
 4-AA 189–190
 Aliskiren 206
 atorvastatin calcium salt 197–199
 (*R*)-1-(3,5-bis(trifluoromethyl)-
 phenyl)ethanol 187–189
 (+)-*cis*-methyl dihydrojasmonate
 207–209
 crizotinib 193
 dorzolamide 186–187
 duloxetine 185–186
 ezetimibe 199–201
 ibuprofen, naproxen, and furbiprofen
 204–205
 L-menthol 201–202
 montelukast sodium 191
 orlistat 198–199
 (*R*)-phenylephrine 194–196
 Ramelteon 205
 rivastigmine 190–191
 sacubitril 202–203
 reduction products 226–230
 β -ketosulfonamides 162

1,2-(α -ketotetramethylene) ferrocene
239

kigamycin A 238
Klabunovskii's approach 8

l

lactic acid 3, 340
leukotriene receptor antagonist (LTRA)
191
ligand acceleration (LA) effect 109,
311
L-menthol 201–202
(-)-lycoramine 136

m

Malus 1
Meerwein–Ponndorf–Verley reduction
reaction 228
Merck's approach 180
mesoporous alumina 318
metabotropic glutamate receptor 5
(mGluR5) 243
metal-free asymmetric hydrogenations
294
methanolysis 332
2-methoxyacetophenone 231
4-methoxy-6-methyl-2-pyrone 314
methyl α -acetamidocinnamate 26
methyl acetamidoacrylate 318
3-methyl-2-butanone 61
(+)-*cis*-methyl dihydrojasmonate
207–209
methyl 2-propionylacetate 323, 324
2-methylpyrrolidine 297
methyl-pyruvate (MP) 309
(*S*)-metolachlor 210
mGluR5 receptor modulator 243
micromesh continuous reactor 326
microreactors 313, 326, 328, 330, 333
mirabalin 147
Mn(I)-chiral PNP pincer ligand system
64
molecular asymmetry
aliphatic organic compounds 3
anomalous dispersion method 2
Biot's Law 2
integrant molecule 1
paratartaric acid 2
plane-polarized light 2

monodentate phosphoramidite ligand
42, 260, 286
monodentate phosphorus ligands 33–34
MonoPhos-based multitopic ligands 329
Montelukast 99, 191–192, 233, 234
multistep flow reaction sequence 332

n

NADH 340
NADPH 340
2-naphthalenecarbaldehyde 358
 α -naphthyl/diphenylbenzene sulfonamide
catalyst 163
naphthyl-ketones 231
1-naphthyl ketones 106
Naproxen 204–205
N-heterocyclic carbene-oxazoline
bidentate ligand 41
 β -nitroacrylates 346
Noyori catalysts 185, 221
N-pentafluorobenzenesulfonyl-1,2-
diamine 106
N-(*p*-toluenesulfonyl)-1,2-
diphenylethylenediamine
(TsDPEN) ligand 129
N-substituted diarylmethanimines 282
N-substituted dibenzo[*b,e*]azepine-
6,11-dione 235, 236
N-tosyl-1,2-diphenylethane-1,2-diamine
(TsDPEN) 285

o

octahydrobinaphthyl-moiety 319
Omarigliptin 134, 242
organocatalysts 30, 255, 308, 329–331
organocatalytic asymmetric transfer
hydrogenation methods
cascade reaction 359–365
C=C bond reductions 341
C=N bond reductions 347
dearomatization 365–369
Orito-reaction 313
Orlistat 198–199
ortho-hydroxy imine 247
oxazoline-carboxylate ligand 116
oxazoline-phosphonite 39
3-(2-oxo-arylethyl)isobenzofuran-
1(3H)-ones 166
 α -oxophosphonates 80–83

p

palladium acetate 288
 palladium catalysts 46–48, 287–288
p-anisidine 350
 paratartaric acid 2, 3
 phenanthridines 259, 269, 273
 1,10-phenanthrolines 269, 270, 366
 α -phenylcinnamic acid 314
 (*R*)-phenylephrine 194–196
 1-phenyl-1,2-propanedione 309, 311
 2-phenylquinoline 368, 369
 phosphine-free chiral diamine ligands 259
 phosphine-oxazoline ligands 38, 49, 90, 96, 97, 100, 110
 phosphine-phosphite ligands 31–33, 319
 phosphine-phosphoramidite ligand 31, 32, 81, 318
 phosphines 12, 56, 119
 phosphorus chirality 12
 phosphotungstic acid (PTA) 317
 phtalide derivatives 166
 Pictet–Spengler cyclizations 344
 pinacolone 61
 pincer ligands 64, 101, 104, 111, 117, 119, 121
 polymer-supported metal catalyst 57, 58
 prochiral functionalized alkenes 45
 prochiral hydantoins 48
 product inhibition 180
 2-propanol 55, 59, 61, 73, 74, 339
 propargylic ketones 222
 propargyl ketones 221
cis- β -(purin-9-yl)cyclopentanols 140
 pyrazines 263–265
 pyrazol-5-ols 272
 pyridines 263–265, 268, 275, 363
 pyridyl ketones 107, 115, 236
 pyridyl *N*-oxide ketones 236
 pyrroles 265–267
 pyruvic acid 340, 341

q

α -quartz 2
 quinoline derivatives 255
 quinolines 257, 366
 quinoxalines 260
 3-quinuclidinone 77

r

racemic acyl phosphonates 166
 racemic chromanones 247
 Ramelteon 205, 206
 Ramipril 178–179
 reduction/lactonization sequence 163
 reductive Michael–Tishchenko cascade 365
 regioisomeric α -amido β -keto esters 165
 Resolution-Racemization-Recycle (RRR) synthesis 185
 rhodium catalysts 14, 15, 25–36, 287
 rhodium complexes 25, 88, 113, 114, 292, 319
 Rh–PennPhos system 58, 59
 (+)-Ricciocarpin A 365
 rivastigmine 190–191
 (*S*)-rivastigmine 99, 356
 Robinson–Michael addition reaction 8
 Rolapitant 187
 Ru-7 complex 64
 Ru-diphosphine/diamine complexes 66, 67
 Ru-diphosphine/diamine systems 66, 77
 Ru–DPEphos/(*S,S*)-BIDN Complex 67
 ruthenium asymmetric hydrogenations 16–18
 ruthenium catalysts 43
 chiral trifluoromethyl-functionalised amines 289
 immobilisation options 290
 N-sulfonyl-1,2-diphenylethane-1,2-diamine-type ligand 291
 polymeric functionalization 291
 pybox and monodentate phosphite ligands 291
 ruthenium-catalyzed asymmetric hydrogenation 88, 135, 149, 186

s

sacubitril 202–203
 self-assembled diphosphine ligands 33
 self-supporting approach 328
 serotonin norepinephrine reuptake inhibitors (SNRIs) 156, 157
 sitagliptin 179–181
 sodium ammonium tartrate 2
 sodium borohydride 95

- Solifenacin 76, 209–210
β-stereocenter 167
β-stereogenic α-hydroxy phosphonic acid derivatives 166
strigolactone (+)-GR24 140, 141
α-substituted aldehydes 168
α-substituted *anti*-β-hydroxyesters 156
cis-α-substituted cycloalkanols 136, 137
1-substituted 1,2-dihydroisoquinolines 367
2-substituted isoquinolines 368
α-substituted β-keto phosphonates 160
β-substituted ketones 167
2-substituted-1-tetralols 137
substrate methyl pyruvate (MP) 325
α-sulfonamide-β-ketones 162, 163
α-(*N*-sulfonylimino) ketones 248
Suvorexant 211
Suzuki–Miyaura cross-coupling 298
symbioramide 146
syn 2-substituted α-alkoxy-β-hydroxy phosphonates 161
syn 2-(1,2,3,4-tetrahydro-1-isoquinolyl) ethanol derivatives 167
- t**
Taranabant 130
tethered catalyst 221–222, 224–225, 248
tethered Ru(II) catalysts
sulfonate group 224
synthetic approaches 224–225
tetradentate ligands 98, 111–112
tetrafluorophenyl-bridged tethered catalysts 225
tetrafluorophenyl-linked complexes 225
tetrahydroisoquinolines 42, 263, 297, 299
- 1,2,3,4-tetrahydro-1,10-phenanthrolines 269
tetrahydropyridines 362
tetrahydroquinolines 257, 259, 354, 362, 363, 365–367
tetralin 339
β-tetralone derivatives 238
α-tetralone-type cyclic ketones 93
(+)-(1*R*,2*R*)-thiamphenicol 149
thiophenes 274
transition state models 60, 61
1,2,3-triazolo-[1,5-*α*]pyridines 268
trichloroethylchloroformate 368
trichloromethyl ketones 239
trickle-bed reactor 310, 318
tridentate pincer ligands 97
(*R*)-1-(3,5-bis(trifluoromethyl)phenyl)ethanol 187–189
β-trifluoromethyl nitroalkenes 347
trifluoromethyl-substituted ketones 231
2,2,4-trimethyltetrahydroquinolines 366
triphenylphosphine 69, 94
trisubstituted allylic derivatives 43
tubular reactors 320, 321
turn-over number (TON) 62
- u**
α,β-unsaturated aldehydes 342, 344, 360
α,β-unsaturated carboxylic acids 314
α,β-unsaturated ketones 66, 339, 362
unsymmetrical benzophenones 106, 235, 236
- x**
X-ray crystallographic analysis 65
XylBINAP/DAIPEN system 66
- z**
Z-imine 349